Metavant Sciences
  • Contact

NEWS

Jul 09
0

Metavant and Poxel Announce Positive Topline Safety and PK/PD Results of Imeglimin in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 3b/4

By Alta Berri | Imeglimin

Trial met its primary objective with imeglimin observed to have a favorable safety and tolerability profile in patients with type 2 diabetes and chronic kidney disease stages 3b/4 Pharmacokinetics (PK)…

Read More
Feb 12
0

Roivant and Poxel Announce Strategic Agreement for Development and Commercialization of Imeglimin in the U.S., Europe, and Additional Countries Worldwide

By Uday Suresh | Imeglimin

Poxel to receive upfront payment of $35 million (approximately €28 million), potential future development and regulatory milestone payments and sales-based payments of up to $600 million (approximately €486 million), and…

Read More
  • Contact


  • Privacy Policy
  • Terms of Use

© 2021 Metavant Sciences.

  • Contact